IL36G and lymphoma: As another mRNA-LNP treatment, mRNA-2752 encoding OX40L, pro-inflammatory cytokines, interleukin-23 (IL-23), and interleukin-36 gamma (IL-36γ) was injected 7 times for 2 weeks with dose escalation, followed by a combination therapy with durvalumab in 126 patients over the age of 18 years with a solid tumor or lymphoma.